Administration of Revuforj

The recommended dosage of Revuforj varies according to the patient's body weight and concomitant use of strong CYP3A4 inhibitors.

Administration of Revuforj

For patients aged 1 year and older with a body weight of ≥40 kg who are not receiving concomitant strong CYP3A4 inhibitors, the recommended dosage of Revuforj is 270 mg orally, twice daily. For those receiving concomitant strong CYP3A4 inhibitors, the dosage is 160 mg orally, twice daily.

For patients aged 1 year and older with a body weight of <40 kg who are not receiving concomitant strong CYP3A4 inhibitors, the recommended dosage of Revuforj is 160 mg/m² body surface area (BSA) orally, twice daily. For those receiving concomitant strong CYP3A4 inhibitors, the dosage is 95 mg/m² BSA orally, twice daily.

Most Common Adverse Reactions of Revuforj include:

Infections, including bacterial and viral infections.

Abnormal liver function test results.

Bleeding.

Nausea and vomiting.

Myalgia.

If you experience certain adverse reactions, your healthcare provider may adjust your dosage, temporarily interrupt, or permanently discontinue Revuforj treatment.

These are not all the possible adverse reactions of Revuforj. For medical advice about adverse reactions, contact your healthcare provider.

Important Information Before Taking:

Revuforj tablets are available in different dosage strengths – your healthcare provider will prescribe the appropriate dosage for you.

Your doctor may prescribe more than one dosage strength of Revuforj tablets for your treatment.

Example: If you are prescribed a 270 mg dose, you will need to take one 160 mg tablet and one 110 mg tablet together, twice daily, to achieve the full required dosage.

Swallow Revuforj tablets whole with water.

Do not cut or chew the tablets.

If you are unable to swallow the tablets whole, you may crush Revuforj tablets and disperse them in water for administration.